多大剂量算合适？干扰素α-2b辅助治疗的疗程应为多久？ - Suppr

Suppr

超能文献

How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?

作者信息

Tarhini Ahmad A, Kirkwood John M

出版信息

J Clin Oncol. 2012 Nov 1;30(31):3773-6. doi: 10.1200/JCO.2012.44.9975. Epub 2012 Sep 24.

DOI:10.1200/JCO.2012.44.9975

PMID:23008298

Abstract

摘要

相似文献

How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?多大剂量算合适？干扰素α-2b辅助治疗的疗程应为多久？

J Clin Oncol. 2012 Nov 1;30(31):3773-6. doi: 10.1200/JCO.2012.44.9975. Epub 2012 Sep 24.

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.辅助治疗用聚乙二醇化干扰素 α-2b 对比观察治疗 III 期黑色素瘤的随机 III 期 EORTC 18991 试验的长期结果。

J Clin Oncol. 2012 Nov 1;30(31):3810-8. doi: 10.1200/JCO.2011.41.3799. Epub 2012 Sep 24.

Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.聚乙二醇化干扰素-α-2b作为日本恶性黑色素瘤患者辅助治疗的I期研究。

J Dermatol. 2016 Oct;43(10):1146-1153. doi: 10.1111/1346-8138.13338.

A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.一例恶性黑色素瘤患者在辅助治疗从β干扰素换用聚乙二醇化α-2b干扰素后发生了多处转移。

Eur J Dermatol. 2018 Feb 1;28(1):115-116. doi: 10.1684/ejd.2017.3169.

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.在无巨淋巴结转移的黑色素瘤患者中，聚乙二醇干扰素 alfa-2b（36 个月）辅助治疗对比低剂量干扰素 alfa-2b（18 个月）：一项开放标签、随机、III 期欧洲皮肤病肿瘤学会（EADO）研究。

Eur J Cancer. 2013 Jan;49(1):166-74. doi: 10.1016/j.ejca.2012.07.018. Epub 2012 Sep 10.

Peginterferon alph-2b (Sylatron) for melanoma.聚乙二醇干扰素α-2b（Sylatron）用于治疗黑色素瘤。

Med Lett Drugs Ther. 2011 Sep 19;53(1373):76.

Adjuvant interferon therapy for malignant melanoma: the debate.恶性黑色素瘤的辅助干扰素治疗：争论

Chin J Cancer. 2010 Nov;29(11):907-13. doi: 10.5732/cjc.010.10169.

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?黑色素瘤的辅助治疗：聚乙二醇化干扰素α-2b是我们一直在期待的药物吗？

Lancet. 2008 Jul 12;372(9633):89-90. doi: 10.1016/S0140-6736(08)61011-9.

Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.静脉注射大剂量干扰素 alfa-2b 治疗可减少黑色素瘤患者循环中的调节性 T 细胞。

Clin Exp Metastasis. 2012 Oct;29(7):801-5. doi: 10.1007/s10585-012-9504-2. Epub 2012 Jul 1.

Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.高危黑色素瘤切除术后接受高剂量干扰素α-2b治疗患者的生活质量

J Clin Oncol. 2009 Aug 20;27(24):e70; author reply e71. doi: 10.1200/JCO.2009.23.3874. Epub 2009 Jul 20.

引用本文的文献

The homeobox family gene signature predicts the prognosis of osteosarcoma and correlates with immune invasion.同源盒基因家族特征可预测骨肉瘤的预后并与免疫浸润相关。

Sci Rep. 2025 Jan 6;15(1):886. doi: 10.1038/s41598-024-84924-w.

Engineered CD4 T cells for in vivo delivery of therapeutic proteins.工程化 CD4 T 细胞用于体内递送治疗性蛋白。

Proc Natl Acad Sci U S A. 2024 Oct;121(40):e2318687121. doi: 10.1073/pnas.2318687121. Epub 2024 Sep 23.

Origin and Therapies of Osteosarcoma.骨肉瘤的起源与治疗

Cancers (Basel). 2022 Jul 19;14(14):3503. doi: 10.3390/cancers14143503.

Cisplatin resistance-related multi-omics differences and the establishment of machine learning models.顺铂耐药相关的多组学差异及机器学习模型的建立。

J Transl Med. 2022 Apr 11;20(1):171. doi: 10.1186/s12967-022-03372-0.

Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials.黑色素瘤的新辅助治疗：新辅助治疗的基本原理及关键临床试验

Ther Adv Med Oncol. 2022 Mar 2;14:17588359221083052. doi: 10.1177/17588359221083052. eCollection 2022.

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.辅助用伊匹单抗（3 或 10 mg/kg）对比高剂量干扰素 α-2b 用于切除的高风险黑色素瘤的 III 期研究：北美协作组 E1609。

J Clin Oncol. 2020 Feb 20;38(6):567-575. doi: 10.1200/JCO.19.01381. Epub 2019 Dec 27.

Current and Emerging Targets in Immunotherapy for Osteosarcoma.骨肉瘤免疫治疗的当前及新出现的靶点

J Oncol. 2019 Jan 1;2019:7035045. doi: 10.1155/2019/7035045. eCollection 2019.

Does intensified chemotherapy increase survival outcomes of osteosarcoma patients? A meta-analysis.强化化疗能否提高骨肉瘤患者的生存结局？一项荟萃分析。

J Bone Oncol. 2018 May 22;12:54-60. doi: 10.1016/j.jbo.2018.04.001. eCollection 2018 Sep.

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.一种独特的基因表达特征在黑色素瘤患者的肿瘤阳性或肿瘤阴性前哨淋巴结中存在显著差异表达。

Melanoma Res. 2017 Oct;27(5):429-438. doi: 10.1097/CMR.0000000000000383.

Adjuvant Therapy for Melanoma.黑色素瘤的辅助治疗

Curr Oncol Rep. 2017 May;19(5):36. doi: 10.1007/s11912-017-0594-5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验